ArticleBMC infectious diseases2012
Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the Netherlands.
Article in BMC infectious diseases, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial.BMJ (Clinical research ed.) · 2015Trial
- Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.European journal of pediatrics · 2013Trial
- Overview of meningococcal epidemiology and national immunization programs in children and adolescents in 8 Western European countries.Frontiers in pediatrics · 2022Article
- Detection of Neisseria meningitidis in saliva and oropharyngeal samples from college students.Scientific reports · 2021Article
- The epidemiology of invasive meningococcal disease and the utility of vaccination in Malta.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020Article
- Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies.Human vaccines & immunotherapeutics · 2019Review
- Protection Against Invasive Infections in Children Caused by Encapsulated Bacteria.Frontiers in immunology · 2018Review
- Meningococcal disease epidemiology in Australia 10 years after implementation of a national conjugate meningococcal C immunization programme.Epidemiology and infection · 2016Article
- Routinely vaccinating adolescents against meningococcus: targeting transmission & disease.Expert review of vaccines · 2016Review
- Impact of vaccination on meningococcal epidemiology.Human vaccines & immunotherapeutics · 2016Review
- Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands.International journal of health policy and management · 2015Article
- Modelled evaluation of multi-component meningococcal vaccine (Bexsero®) for the prevention of invasive meningococcal disease in infants and adolescents in the UK.Epidemiology and infection · 2014Article
- The impact of protein-conjugate polysaccharide vaccines: an endgame for meningitis?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2013Review
- The endgame for serogroup a meningococcal disease in Africa?Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2013Article
- Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the Netherlands.PloS one · 2013Article
- How the interval between prime and boost injection affects the immune response in a computational model of the immune system.Computational and mathematical methods in medicine · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe first meningococcal serogroup C (MenC) conjugate vaccine was licensed in 1999 and introduced in the United Kingdom. Countries that have implemented the MenC vaccine since then in their national immunisation programmes use different schedules. Nevertheless, all involved countries seem to experience substantial declines in the incidence of MenC disease. DISCUSSION: Since 2001, the MenC conjugate vaccine has been implemented in the Netherlands by offering a single dose to all children aged 14 months. Prior to the introduction of the vaccine into the national immunisation programme, a catch-up vaccination campaign was initiated in which a single dose of the MenC conjugate vaccine was offered to all children aged from 14 months up to and including 18 years. Since then, there has been no report of any case of MenC disease among immunocompetent vaccinees. Administration of a single dose of MenC conjugate vaccine after infancy could be beneficial considering the already complex immunisation schedules with large numbers of vaccinations in the first year of life. The present paper deals with the advantages and critical aspects of a single dose of the MenC conjugate vaccine. SUMMARY: A single dose of MenC conjugate vaccine at the age of 14 months in combination with a catch up vaccine campaign appeared to be a successful strategy to prevent MenC disease in the Netherlands, thereby confirming that a single dose of the vaccine could sufficiently protect against disease. Nevertheless, this approach can only be justified in countries with a relatively low incidence of serogroup C meningococcal disease in the first year of life. Furthermore, a good surveillance programme is recommended for timely detection of vaccine breakthroughs and outbreaks among non-vaccinees, since long-term protection after a single dose in the second year of life cannot currently be guaranteed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.